Vertex's cystic fibrosis drug positive in Phase IIa
This article was originally published in Scrip
Executive Summary
Vertexhas announced additional positive Phase IIa results for its investigational drug, VX-770, in cystic fibrosis (CF) patients who carry the G551D CFTR (cystic fibrosis transmembrane conductance regulator) gene mutation. The findings were presented at the North American Cystic Fibrosis Conference in Orlando on October 23rd.